Search General Info
Search Education
Search Partnering Companies
Nanoscope Therapeutics
11:45 AM - 12:00 PM (EDT), Wednesday, June 7, 2023 ・ Session Room 104C
![BIO International Convention](/sites/default/files/2021-09/_BIO_CONV_Logo-White.png)
Nanoscope Therapeutics is a late-stage clinical company developing an optogenetic platform to restore sight in patients suffering from inherited retinal disease and dry-AMD using ambient light-sensitive molecules and light-assisted gene therapy.
Nanoscope's lead asset, MCO-010, is currently in a pivotal trial in RP (retinitis pigmentosa) with data expected in Q1 2023. Additionally, a Ph2 trial evaluating MCO-010 in Stargardt macular degeneration is also being initiated. MCO-020, Nanoscope's follow-on asset for geographic atrophy in late-stage AMD patients, is currently in IND enabling studies.
Nanoscope utilizes ambient light-sensitive molecules to re-sensitize the retina toward low light levels. The Company's light-assisted gene therapy is highly targeted to geographic atrophies without perturbing the intact retina circuitry.
Nanoscope's lead asset, MCO-010, is currently in a pivotal trial in RP (retinitis pigmentosa) with data expected in Q1 2023. Additionally, a Ph2 trial evaluating MCO-010 in Stargardt macular degeneration is also being initiated. MCO-020, Nanoscope's follow-on asset for geographic atrophy in late-stage AMD patients, is currently in IND enabling studies.
Nanoscope utilizes ambient light-sensitive molecules to re-sensitize the retina toward low light levels. The Company's light-assisted gene therapy is highly targeted to geographic atrophies without perturbing the intact retina circuitry.
![](https://www.abstractscorecard.com/uploads/Tasks/upload/20525/EOISBJNL-1539776-1-JPG.jpg)
Ticker:
Not Provided
Exchange:
Not Provided
Company Type:
Not Provided
Company Website:
Company HQ State:
TX
Company HQ Country:
United States
Year Founded:
2017
Main Therapeutic Focus:
Gene/Cell Therapy
Lead Product in Development:
MCO-010 Optogenetic Gene Therapy for Inherited Retinal Dystrophies (IRDs)
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
![](https://www.conferenceharvester.com/uploads/harvester/photos/EOISBJNL-Presenter-BhattacharyaS.jpg)
BIO DOUBLE HELIX SPONSORS
![Sanofi logo](/sites/default/files/2022-05/Sanofi_Color_jpg_Double%20Helix.jpg)
![Eli Lilly and Company](/sites/default/files/2019-09/Eli%20Lilly%20and%20Company.png)
![Amgen logo](/sites/default/files/2022-05/Amgen_Color_png_Double%20Helix.png)
![Genentech logo](/sites/default/files/2022-05/Genentech_Color_png_Double%20Helix.png)
![Merck_logo_2022](/sites/default/files/2022-10/Merck_Color_.png)
![Avantor](/sites/default/files/2021-06/Avantor-BIO-DH-578.png)
![GSK logo](/sites/default/files/2023-04/gsk_color_png.png)
BIO HELIX SPONSORS
![Johnson and Johnson](/sites/default/files/2021-06/Johnson-Johnson-BIO-DH-578.png)
![Takeda logo](/sites/default/files/2022-05/Takeda_Color_jpg_Premier.jpg)
![Travere logo](/sites/default/files/2022-05/Travere_Color_png_Helix%20large.png)
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2024 All Rights Reserved